Health Care & Life Sciences » Biotechnology | Keryx Biopharmaceuticals Inc.

Keryx Biopharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
46,732.00
111,518.00
123,145.00
161,095.00
163,440.00
Depreciation, Depletion & Amortization
54.00
306.00
596.00
1,005.00
937.00
Other Funds
-
-
15.00
-
302.00
Funds from Operations
40,806.00
83,555.00
91,880.00
78,661.00
78,493.00
Changes in Working Capital
6,487.00
2,554.00
35,577.00
7,943.00
14,996.00
Net Operating Cash Flow
34,319.00
81,001.00
127,457.00
86,604.00
93,489.00
Capital Expenditures
346.00
1,489.00
2,777.00
2,074.00
1,257.00
Purchase/Sale of Investments
-
11,508.00
11,508.00
-
-
Net Investing Cash Flow
346.00
12,997.00
8,731.00
2,074.00
1,257.00
Issuance/Reduction of Debt, Net
-
-
125,000.00
-
-
Net Financing Cash Flow
75,684.00
112,586.00
244,732.00
198.00
76,462.00
Net Change in Cash
41,019.00
18,588.00
126,006.00
88,480.00
18,284.00
Free Cash Flow
34,665.00
82,490.00
130,234.00
88,678.00
94,746.00
Deferred Taxes & Investment Tax Credit
-
700.00
90.00
80.00
235.00
Change in Capital Stock
75,684.00
112,586.00
119,747.00
198.00
76,764.00

About Keryx Biopharmaceuticals

View Profile
Address
12th Floor
Boston Massachusetts 02210
United States
Employees -
Website http://www.keryx.com
Updated 09/14/2018
Keryx Biopharmaceuticals, Inc. engages in the manufacture, development, and commercialization of medicines for use in treating human diseases. Its product is the Auryxia tablet. The company was founded in October 1998 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.